Literature DB >> 19236612

Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations.

S E Manley1, K A Sikaris, Z X Lu, P G Nightingale, I M Stratton, R A Round, V Baskar, S C L Gough, J M Smith.   

Abstract

AIM: To determine whether glycated haemoglobin (HbA(1c)) can be used in combination with fasting plasma glucose (FPG) for the diagnosis of diabetes in patients with impaired fasting glucose (IFG) and in a broader spectrum of patients.
METHODS: An algorithm was derived from oral glucose tolerance test (OGTT) capillary samples in 500 consecutive UK patients with IFG by World Health Organization criteria. It was validated in a further 500 UK patients and, with venous specimens, in 1175 unselected Australian patients.
RESULTS: The derivation cohort was aged 61 years (50-69 years) (median IQ range) with 52% male and 12% South Asian. Diabetes Control and Complications Trial-aligned HbA(1c) was 6.2% (5.8-6.6%) (reference interval < 6.0%) and FPG 6.7 mmol/l (6.3-7.2 mmol/l). FPG was in the diabetes range in 36% of patients, with an OGTT identifying a further 12% with diabetes. The derived algorithm, (HbA(1c) >or= 6.0% with FPG < 7.0 mmol/l) identified those patients requiring an OGTT to diagnose diabetes. When applied to the UK validation cohort, sensitivity was 97% and specificity 100%. The algorithm was equally effective in the unselected group, aged 59 years (49-68 years) and 54% male, with sensitivity 93% and specificity 100%. HbA(1c) was 6.0% (5.6-6.6%) and FPG 6.0 mmol/l (5.3-6.8 mmol/l), with 26% having IFG. Use of the algorithm would reduce the number of OGTTs performed in the UK validation cohort by 33% and by 66% in the Australian patients studied.
CONCLUSIONS: Use of this algorithm would simplify procedures for diagnosis of diabetes and could also be used for monitoring pre-diabetes. Validation is now required in other populations and patient groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236612     DOI: 10.1111/j.1464-5491.2008.02652.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening.

Authors:  Ben Schöttker; Elke Raum; Dietrich Rothenbacher; Heiko Müller; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2011-09-27       Impact factor: 8.082

2.  Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study.

Authors:  Abel N Kho; M Geoffrey Hayes; Laura Rasmussen-Torvik; Jennifer A Pacheco; William K Thompson; Loren L Armstrong; Joshua C Denny; Peggy L Peissig; Aaron W Miller; Wei-Qi Wei; Suzette J Bielinski; Christopher G Chute; Cynthia L Leibson; Gail P Jarvik; David R Crosslin; Christopher S Carlson; Katherine M Newton; Wendy A Wolf; Rex L Chisholm; William L Lowe
Journal:  J Am Med Inform Assoc       Date:  2011-11-19       Impact factor: 4.497

3.  Lifestyle interventions for the treatment of class III obesity: a primary target for nutrition medicine in the obesity epidemic.

Authors:  George L Blackburn; Samuel Wollner; Steven B Heymsfield
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

Review 4.  HbA1c for screening and diagnosis of diabetes mellitus.

Authors:  Trefor Higgins
Journal:  Endocrine       Date:  2012-08-21       Impact factor: 3.633

5.  Influences on the uptake of diabetes screening: a qualitative study in primary care.

Authors:  Helen Eborall; Margaret Stone; Navneet Aujla; Nicholas Taub; Melanie Davies; Kamlesh Khunti
Journal:  Br J Gen Pract       Date:  2012-03       Impact factor: 5.386

6.  Circadian blood pressure variability in type 1 diabetes subjects and their nondiabetic siblings - influence of erythrocyte electron transfer.

Authors:  Elena Matteucci; Cristina Consani; Maria Chiara Masoni; Ottavio Giampietro
Journal:  Cardiovasc Diabetol       Date:  2010-10-05       Impact factor: 9.951

7.  Validity of glycated hemoglobin in screening and diagnosing type 2 diabetes mellitus in Chinese subjects.

Authors:  Yun Yu; Xiao-Jun Ouyang; Qing-Lin Lou; Liu-Bao Gu; Yong-Zhen Mo; Gary T Ko; Chun-Chung Chow; Wing-Yee So; Ronald Ma; Alice Kong; Nicola Brown; Jennifer Nan; Juliana Chan; Rong-Wen Bian
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

8.  Hemoglobin A1c for the diagnosis of diabetes: To replace or to guide oral glucose tolerance tests?

Authors:  Hung-Yuan Li; Wen-Ya Ma; Jung-Nan Wei; Mao-Shin Lin; Shyang-Rong Shih; Chi Sheng Hung; Cyue-Huei Hua; Lee-Ming Chuang
Journal:  J Diabetes Investig       Date:  2012-06-06       Impact factor: 4.232

9.  Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV.

Authors:  Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén
Journal:  BMJ Open       Date:  2016-12-08       Impact factor: 2.692

10.  Prevalence of undiagnosed type 2 diabetes in patients admitted with acute coronary syndrome: the utility of easily reproducible screening methods.

Authors:  Muhammad A Karamat; Umar Y Raja; Susan E Manley; Alan Jones; Wasim Hanif; Abd A Tahrani
Journal:  BMC Endocr Disord       Date:  2017-01-23       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.